Demis Hassabis & Isomorphic Labs

Demis Hassabis: Hassabis transitions from CEO to Chair of Alphabet Inc. — Google DeepMind and Chief Scientist of Alphabet, focusing on AGI strategy. He remains a key figure, but his reduced operational role may affect DeepMind's direction.

Isomorphic Labs: Isomorphic Labs, the AI drug discovery company, remains under Hassabis's leadership. He will spend more time there, potentially accelerating its work in biomedical applications.

Demis Hassabis: Demis Hassabis, CEO of Alphabet Inc. — Google DeepMind and Nobel laureate, remains at the company but oversees the strategic shift away from the AlphaFold model.

Isomorphic Labs: Isomorphic Labs, Alphabet's drug discovery spinout, gains some former AlphaFold researchers, potentially benefiting from their expertise.

Demis Hassabis: Demis Hassabis, CEO of Alphabet Inc. — Google DeepMind, acknowledges the competitive AI talent market but maintains confidence in Alphabet Inc.'s ability to attract and retain top talent, attempting to reassure investors.

Isomorphic Labs: Some members of John Jumper's protein-folding research team have moved to Isomorphic Labs, an Alphabet spinout, indicating internal talent shifts within Alphabet's AI ecosystem.